Physician profile
Harry Kipperman
NPI 1053321786
$2,537.77
in general payments reported to CMS, 2019-2025
30 companies · $484 in 2025
The $484 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $314 · 2021: $216 · 2022: $243 · 2023: $394 · 2024: $529 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $328.74 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $314.92 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $212.35 | 2023-2025 | Azstarys |
| Cranial Technologies, INC | $203.62 | 2019-2025 | Doc Band |
| Pfizer INC. | $183.07 | 2019-2025 | |
| Sanofi Pasteur INC. | $172.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.36 | 2019-2022 | |
| Kaleo, INC. | $132.74 | 2020-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $112.27 | 2019-2025 | Rotarix, Bexsero, Penmenvy |
| Ironshore Pharmaceuticals INC. | $76.25 | 2019-2023 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $68.71 | 2023-2024 | Ycanth |
| Phadia US INC. | $68.46 | 2022-2025 | Immunocap |
| Vertical Pharmaceuticals, LLC | $65.39 | 2020-2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $47.57 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $40.98 | 2024-2025 | Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $40.35 | 2023 | Genexpert |
| Shire North American Group INC | $34.90 | 2019 | |
| Sobi, INC | $34.59 | 2019-2020 | |
| Alk-Abello, INC | $34.40 | 2023 | Grastek, Ragwitek, Odactra |
| Mission Pharmacal Company | $33.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.57 | 2024-2025 | |
| Organon LLC | $23.80 | 2025 | |
| Qol Medical, LLC | $23.77 | 2022 | |
| Abbvie INC. | $23.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.97 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2024 | Zoryve |
| Genentech USA, INC. | $16.07 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.73 | 2025 | Neffy |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 | |
| Adlon Therapeutics L.P. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Kipperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.